Enanta Pharmaceuticals (ENTA) Income towards Parent Company (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Income towards Parent Company of -$13.1 million for Q1 2026, up 42.19% year-on-year from -$9.2 million in Q1 2025, and down 9.66% on a QoQ basis from -$11.9 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Income towards Parent Company data on file, last reported at -$13.1 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company rose 42.19% year-over-year to -$13.1 million; the trailing twelve-month figure through Mar 2026 stood at -$62.0 million (up 35.58% YoY), and the FY2025 full-year result was -$81.9 million, up 29.32% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$13.1 million, down from -$11.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$11.9 million in Q4 2025 and bottomed at -$39.1 million in Q2 2023.
- The 5-year median for Income towards Parent Company is -$28.1 million (2023), against an average of -$26.4 million.
- Peak annual rise in Income towards Parent Company reached 67.83% in 2022, while the deepest fall reached 31.95% in 2022.
- A 5-year view of Income towards Parent Company shows it stood at -$29.0 million in 2022, then slipped by 15.25% to -$33.4 million in 2023, then soared by 33.28% to -$22.3 million in 2024, then soared by 46.44% to -$11.9 million in 2025, then dropped by 9.66% to -$13.1 million in 2026.
- The last three Income towards Parent Company figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.09 Mn |
| Dec 31, 2025 | -11.94 Mn |
| Sep 30, 2025 | -18.70 Mn |
| Jun 30, 2025 | -18.26 Mn |
| Mar 31, 2025 | -22.64 Mn |
| Dec 31, 2024 | -22.29 Mn |
| Sep 30, 2024 | -28.63 Mn |
| Jun 30, 2024 | -22.66 Mn |
| Mar 31, 2024 | -31.16 Mn |
| Dec 31, 2023 | -33.41 Mn |
| Sep 30, 2023 | -28.11 Mn |
| Jun 30, 2023 | -39.07 Mn |
| Mar 31, 2023 | -37.66 Mn |
| Dec 31, 2022 | -28.99 Mn |
| Sep 30, 2022 | -26.35 Mn |
| Jun 30, 2022 | -31.70 Mn |
| Mar 31, 2022 | -33.59 Mn |
| Dec 31, 2021 | -30.12 Mn |
| Sep 30, 2021 | -81.90 Mn |
| Jun 30, 2021 | -24.02 Mn |
| Mar 31, 2021 | -36.27 Mn |
| Dec 31, 2020 | -8.33 Mn |
| Sep 30, 2020 | -29.34 Mn |
| Jun 30, 2020 | -14.27 Mn |
| Mar 31, 2020 | -6.01 Mn |
| Dec 31, 2019 | 13.44 Mn |
| Sep 30, 2019 | 9.19 Mn |
| Jun 30, 2019 | 7.04 Mn |
| Mar 31, 2019 | 4.15 Mn |
| Dec 31, 2018 | 26.01 Mn |
| Sep 30, 2018 | 27.42 Mn |
| Jun 30, 2018 | 20.29 Mn |
| Mar 31, 2018 | 12.56 Mn |
| Dec 31, 2017 | 11.69 Mn |
| Sep 30, 2017 | 73.40 Mn |
| Jun 30, 2017 | -16.63 Mn |
| Mar 31, 2017 | -12.52 Mn |
| Dec 31, 2016 | -8.06 Mn |
| Sep 30, 2016 | -3.45 Mn |
| Jun 30, 2016 | -208,000.00 |
| Mar 31, 2016 | 1.46 Mn |
| Dec 31, 2015 | 45.66 Mn |
| Sep 30, 2015 | 2.55 Mn |
| Jun 30, 2015 | 1.56 Mn |
| Mar 31, 2015 | 68.79 Mn |
| Dec 31, 2014 | 99.01 Mn |
| Sep 30, 2014 | -5.14 Mn |
| Jun 30, 2014 | 19.81 Mn |
| Mar 31, 2014 | -5.20 Mn |
| Dec 31, 2013 | -5.37 Mn |
| Sep 30, 2013 | -4.44 Mn |
| Jun 30, 2013 | -4.14 Mn |
| Mar 31, 2013 | -3.96 Mn |
| Dec 31, 2012 | 21.94 Mn |
| Sep 30, 2012 | -4.06 Mn |
| Jun 30, 2012 | -3.48 Mn |
| Mar 31, 2012 | 32.11 Mn |